Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04480398|
Recruitment Status : Completed
First Posted : July 21, 2020
Last Update Posted : July 22, 2020
Coronavirus disease 2019 (Covid-19) has been declared global emergency with immediate safety, preventative and curative measures to control the spread of virus. Confirmed cases are treated with clinical management as they are diagnosed but so far, there is no effective treatment or vaccine yet for Covid-19.
With recommended guidelines of AYUSH Ministry, India, the use of Ayurveda for Covid-19 has increased; however, its efficacy and safety in Covid-19 confirmed patients remain unclear.
Present study examined the efficacy and safety of one of the recommended Ayurveda drug (Guduchi Ghan Vati) compared with standard care for patients with asymptomatic Covid-19 patients.
|Condition or disease||Intervention/treatment|
|Covid19 Asymptomatic Condition||Drug: Guduchi Ghan Vati|
|Study Type :||Observational|
|Actual Enrollment :||91 participants|
|Official Title:||A Retrospective Study on Efficacy and Safety of Guduchi Ghan Vati for Covid-19 Asymptomatic Patients|
|Actual Study Start Date :||May 12, 2020|
|Actual Primary Completion Date :||June 15, 2020|
|Actual Study Completion Date :||July 3, 2020|
Guduchi Ghan Vati was given to Covid patients 2 tablets (500 mg each) twice daily were given orally after meal for 28 days. Guduchi ghan vati is a powdered aqueous extract of Tinospora cordifolia in tablet form and prepared in GMP certified Pharmacy of the University, following standard protocol.
Drug: Guduchi Ghan Vati
Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia.
Other Name: Giloy Ghan Vati
Standard care for asymptomatic confirmed cases is isolation (to contain virus transmission) and clinical monitoring as per recommended Guidelines.
- Virologic clearance [ Time Frame: 21 days ]Virologic clearance indicates the duration from the first Covid-19 positive result to the first Covid-19 negative result
- Change in the number of patients going from asymptomatic to moderately disease [ Time Frame: 10-days of hospital admission ]change in the number of patients going from asymptomatic to moderately disease
- Hospital Stay [ Time Frame: 21 days ]Total duration of stay in hospital for complete recovery
- Clinically relevant adverse effects [ Time Frame: 21-days ]Clinically relevant adverse effects of Guduchi Ghan Vati (Disability, Discomfort reported)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04480398
|Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University|
|Jodhpur, Rajasthan, India|
|Study Chair:||Parashar Sharma||Samta Ayurveda Prakoshtha|
|Study Chair:||Jaydeep Joshi||Aarogyam UK|
|Study Director:||Neha Sharma||Aarogyam UK|
|Principal Investigator:||Abhimanyu Kumar||Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University|